Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Children with autism are often treated with psychiatric drugs. These medications have been shown to improve their language and social function, and are important in improving their quality of life. In many cases it is difficult to determine the best drug dose, and a favorable response occurs in only 30%-70% of individuals, with many children suffering significant adverse drug reactions.

Pharmacogenetics is the study of the role of different genes on drug behavior. The cytochrome P450 is the most important enzyme, involved in the metabolism of a vast number of drugs, including psychiatric medications. The multiple variations in this gene can result in the different response observed in different patients, even when treated with similar doses of the drug.

Hypothesis(es):

Mapping the different types of cytochrome P450 gene, in children with autistic disorders will improve the rate of success of medical treatment, and prevent adverse drug reactions.

Potential Impact:

If successful, our study can help thousands of children and their families by developing a system of "tailored medicine" that is based on the specific activity of the various enzymes present in that particular patient. Better medical treatment will facilitate better daily interactions with the children and enhance their quality of life. Furthermore, recognizing children that are resistant to medication will prevent unnecessary use of drugs.

It should be noted this is the first study focusing on children receiving psychiatric medications using pharmacogenetics. Found to be effective, this method can also be applied to other groups of medications and to other patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response

NCT02414451

Autism

WITHDRAWN NA

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

NCT00198107

Autistic Disorder

COMPLETED PHASE3

Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response

NCT02871349

Autism Spectrum Disorder

COMPLETED EARLY_PHASE1

Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy

NCT00166621

Autism

COMPLETED PHASE1/PHASE2

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

NCT01337700

Autism Spectrum Disorder Asperger Syndrome Aspergers Syndrome

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Neuroleptic Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neuroleptics

Children with autistic spectrum disorder, treated with neuroleptics

Genotyping of Cytochrome P450

Intervention Type OTHER

Genotyping of Cytochrome P450

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genotyping of Cytochrome P450

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\> 3 years
* Diagnosed with autism
* Treated with neuroleptics

Exclusion Criteria

* Patients with known allergy to second generation neuroleptics.
* Patients with moderate to severe renal insufficiency
* Patients with liver disease
* Patients with active cardiac disease
* Patients with hypertension not responsive to anti-hypertensive therapy
* Patients with substance abuse
* Suicidal patients

Minimum Eligible Age

3 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No